RESEARCH OVERVIEW – SOLID TUMORS

As published in numerous academic journals, The DigniCap Scalp Cooling System has been shown to be safe and effective in reducing chemotherapy-induced alopecia in cancer patients with solid tumors. 

Of 226 patients with various solid tumors and undergoing different chemotherapies 65% showed no visible hair loss.

As Published
The influence of various parameters on the success of sensor-controlled scalp cooling in preventing chemotherapy-induced alopecia.
Oncology Research and Treatment (Vol. 38. 2015, 489-495)

Schaffrin-Nabe, D, et al.

Summary

  • The analysis of scalp cooling data of 226 patients with various solid tumors and undergoing different chemotherapies revealed that 65% showed no visible hair loss (CTC grades 0–1), which means 2/3 of patients needed no head cover.
  • These findings directly correspond to the results of Rugo et al. study presented at the ASCO Meeting 2015.
  • The type of substance, dose, and combination of the cytostatics used, the patient’s age, menopausal status, and systemic comorbidities with related regular co-medication, as well as hair density significantly influence the success of scalp cooling; a statistical influence was also seen for nicotine abuse. 

Results

  • 226 patients with various solid tumors were treated with different chemotherapy regimens in the (neo)adjuvant or palliative setting simultaneously to scalp cooling.
  • 146 (65%) patients showed a positive effect of scalp cooling with no or only mild alopecia (not visible, chemotherapy-induced alopecia grades 0 and 1) after completing (neo) adjuvant chemotherapy or after a minimum of 3 months of palliative chemotherapy.
  • 28% of the studied 226 patients opted for a wig.
  • The scalp cooling success rate of the 136 patients with breast cancer receiving different (neo) adjuvant chemotherapies was 65% (88 patients).
  • A subgroup of 76 patients treated with epirubicin cyclophosphamide/paclitaxel scalp cooling was successful in 52 (68%) patients.
  • A total of 5 patients developed chemotherapy-induced alopecia grade 2 after epirubicin cyclophosphamide treatment, but experienced complete hair regrowth during subsequent paclitaxel treatment and successfully finished scalp cooling after chemotherapy with chemotherapy-induced alopecia grade 1. 

Conclusion 

Sensor controlled scalp cooling is an effective supportive method to prevent chemotherapy-induced alopecia. It is well tolerated, and in the majority of cases it generates considerable benefit for the patients.

OPERATIONS
Dignitana
10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 877-350-2150

HEADQUARTERS
Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90

HEADQUARTERS
Dignitana S.r.l.
Corso di Porta Nuova, 46
20121 Milan, Italy